2014 American Thoracic Society International Conference
The 2014 American Thoracic Society International Conference in San Diego "will offer the latest information on clinical, basic and translational science in pulmonary, critical care and sleep medicine."
Monotherapy with N-acetylcysteine No Better Than Placebo for Preserving Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.
Recently published study results, when combined with results from previous clinical trials, show treatment with the antifibrotic drug pirfenidone slows disease progression and improves survival in patients with idiopathic pulmonary fibrosis (IPF). These findings, if they lead the FDA to reevaluate and approve this drug, could be a game changer for patients with IPF, a disease marked by a high mortality rate and few treatment options.
Treatment with Dual Bronchodilator Produces Significant Improvements in Lung Function in Patients with COPD
Combination Treatment with Umeclidinium Plus Vilanterol Produces Significant Improvements in Lung Function in Patients with COPD